Evidence map›Paper›PMID 30899803›Full record

ArticleBiochemistry and biophysics reports2019

A cell-based high-throughput screen identifies tyrphostin AG 879 as an inhibitor of animal cell phospholipid and fatty acid biosynthesis.

Raphael A Zoeller, Kathleen Geoghegan-Barek

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Raphael A ZoellerDepartment of Physiology & Biophysics, Boston University School of Medicine, 700 Albany Street, Room W302, Boston, MA, 02118, USA.
Kathleen Geoghegan-BarekDepartment of Physiology & Biophysics, Boston University School of Medicine, 700 Albany Street, Room W302, Boston, MA, 02118, USA.
Boston University · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI CORKEY, BARBARA E. · 1992 to 2021
$25.0M
A high throughput screen for inhibitors of mammalian glycerolipid biosynthesisR01GM107675 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZOELLER, RAPHAEL ANDREW · 2015 to 2017
$933k
NCATS NIH HHS UL1 TR001430NIDDK NIH HHS P30 DK046200NIGMS NIH HHS R01 GM107675
6 · The paper itself

Abstract

Inhibition of animal cell phospholipid biosynthesis has been proposed for anticancer and antiviral therapies. Using CHO-K1 derived cell lines, we have developed and used a cell-based high-throughput procedure to screen a 1280 compound, small molecule library for inhibitors of phospholipid biosynthesis. We identified tyrphostin AG 879 (AG879), which inhibited phospholipid biosynthesis by 85-90% at a concentration of 10 μM, displaying an IC

Indexed as

32Pi, [32P]orthophosphateAFU, Arbitrary fluorescence unitsAG879, Tyrphostin AG 879AnticancerAntiviralCE, Cholesterol esterCL, CardiolipinDrug screeningEGFR, Epidermal growth factor receptorFatty acid biosynthesisHER2, Human epidermal growth factor receptor 2HTS, High-throughput screenP12, 12-(1′-pyrene) dodecanoic acidPA, Phosphatidic acidPC, PhosphatidylcholinePE, PhosphatidylethanolaminePhospholipid biosynthesisPI, PhosphatidylinositolPL, PhospholipidRTK, Receptor tyrosine kinaseTG, TriacylglyceroltrkA, Tropomyosin analogue receptor kinaseTyrphostin AG 879

Identifiers

PMID30899803
PMCPMC6406593
OpenAlexW2921929639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.